Next Article in Journal
Current Issues and Future Technologies in Esophageal Cancer Surgery
Previous Article in Journal
The Comprehensive Analysis of Motor and Neuropsychiatric Symptoms in Patients with Huntington’s Disease from China: A Cross-Sectional Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 1
10.3390/jcm12010208
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hormonal and Reproductive Factors in Relation to Cardiovascular Events in Women with Early Rheumatoid Arthritis

by
Antonia Boman
,
Heidi Kokkonen
,
Ewa Berglin
,
Gerd-Marie Alenius
and
Solbritt Rantapää-Dahlqvist
*
Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, 90187 Umeå, Sweden
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(1), 208; https://doi.org/10.3390/jcm12010208
Submission received: 16 November 2022 / Revised: 15 December 2022 / Accepted: 23 December 2022 / Published: 27 December 2022
(This article belongs to the Section Cardiovascular Medicine)
Browse Figure
Review Reports Versions Notes

Abstract

:
Hormonal and reproductive factors affect the risk for cardiovascular events (CVE) in the general population. Although the risk of CVE is increased in rheumatoid arthritis (RA), the knowledge about the impact of hormonal factors for CVE in RA is sparse. Female postmenopausal patients ≤80 years with early RA were consecutively included in this observational study (n = 803) between 1 January 1996 until 31 December 2017. Questionnaires regarding hormonal factors were distributed from the index date. Data regarding CVE were obtained from the Swedish National Health Register and Cause of Death Register. Associations between CVE and hormonal factors were analyzed using Cox proportional hazard regression. Of the postmenopausal women, 64 women had a CVE after RA onset. The time period from menopause to RA onset was significantly longer for CVE cases with higher proportion of postmenopausal women. In Cox proportional hazard regression models, years from last childbirth and multiparity were associated with higher CVE risk. Adjustments for traditional risk factors did not affect the results except for hypertension. RA onset after menopause and a longer duration from menopause until onset increased the CVE risk. Multiparity was associated with higher CVE risk whilst oral contraceptives decreased the risk. These results can contribute to identification of high-risk patients for CVE beyond traditional risk factors.

1. Introduction

Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD), which contributes to the largest proportion of excess mortality compared with the general population, particularly ischemic heart disease, not fully accounted for by traditional risk factors [1,2,3]. Other CVD manifestations are atherosclerosis, arterial stiffness, coronary arteritis, congestive heart failure, and valvular disease [4,5]. Suggested underlying mechanisms linking the increased risk of CVD to RA besides inflammatory-related mediators, include alterations of lipoproteins, increased oxidative stress, and endothelial dysfunction [6,7]. A number of risk factors are in common between development of RA and of CVD per se such as smoking, air pollution, overweight, increased BMI, and increased CRP, ACPA [8].
Furthermore, there is a difference in traditional risk factors, in general, between men and women, where results increasingly suggest that several reproductive factors associate with later-life CVD [9,10].
In relation to the development of RA, hormonal factors have been analyzed in a number of studies [11,12,13]. The increased prevalence of RA in women compared to men, with a peak incidence that coincides with menopause [11], has led to the hypothesis that hormonal and reproductive factors play an important role in the development of RA [11,14]. However, clinical and experimental studies have shown conflicting results regarding the pathogenic and etiological role of female hormones in RA [11,14]. There are also consistent results suggesting that estrogens have a protective role in disease activity and progression of RA [15,16]. For example, most patients experience disease remission during pregnancy when levels of female sex hormones are high but a relapse during the postpartum period [15,16]. Interestingly, estrogens have both pro- and anti-inflammatory effects that may explain their paradox in RA pathogenesis. While estrogens are potent inducers of B cell survival and antibody production, they also decrease the production of key cytokines for RA pathogenesis, such as IL-6, TNFα, and IL-1β [17]. The peak incidence of onset in females coincides with menopause, when the ovarian production of sex hormones drops markedly [18].
Other hormones, such as androgens, progesterone or prolactin, also exert effects on the immune system. The postmenopausal stage, an early age at menopause, the post-partum period, and the use of anti-estrogen agents are associated with RA onset. All these phenomena have in common an acute decline in ovarian function and/or in estrogen bioavailability [11].
Several hormonal and reproductive factors in women of the general population have been shown to associate with the risk of developing later-life CVD, although findings are diverse and inconsistent [10,19,20,21,22,23]. An increased risk for CVD later in life has been associated with early menarche and menopause [10,19,20], parity (i.e., number of childbirths) [20,21], childbirths at an early age [22], and the use of oral contraceptives [23]. Protective hormonal and reproductive factors for CVD have also been reported, for example, in women who had breastfed earlier in life, suggesting long-term health benefits for the women [24]. The conflicting results can partly be explained by differences in treatment and differences in populations over time regarding hormonal and reproductive factors. To evaluate total estrogen exposure, several indices have been constructed [25] and a majority of studies have defined this as the reproductive lifespan, i.e., the time period between menarche and menopause [25,26,27]. A longer reproductive lifespan has also been suggested to be protective against CVD [25,28]. Conclusive findings regarding the associations of hormonal factors and CVD in patients with RA are however lacking.
In the light of studies concerning hormonal and/or reproductive factors for both CVD per se and for RA, we have analyzed the associations between hormonal and reproductive factors, and RA disease-related factors for the risk of developing CVE in women with early RA. We have, as one of the first studies focused on factors previously analyzed for women of the general population, to explore the impact of these factors in women with RA for affection with CVE.

2. Materials and Methods

2.1. Subjects

Patients from the northern region of Sweden (rheumatology departments at five hospitals) with early RA (symptoms ≤12 months) fulfilling the 1987 American Rheumatism Association (ARA) classification criteria for RA [29] were consecutively included into the study and registered in the Swedish Rheumatology Quality Register [30] since 1 January 1996. This study included women from the early RA cohort from 1 January 1996 until 31 December 2017. The patients were followed from the index date until death or the end of the study.
Data regarding Disease Activity Score (DAS28) [31] including swollen (SJC) and tender joint count (TJC), patient’s global assessment (visual analogue scale) and erythrocyte sedimentation rate (ESR; mm/hour) were assessed at inclusion (index date) and at 6, 12, 18, and 24-months during follow-up continuously. The patients were treated with the aim of achieving remission/low disease activity [32] identified by the patient’s physician. The treatment constituted of conventional disease-modifying antirheumatic drugs (csDMARDs; azathioprine, chloroquine, cyclosporine, leflunomide, methotrexate, myocrisine, and sulfasalazine), corticosteroids, and biological (b)DMARDs (abatacept, adalimumab, anakinra, certolizumabpegol, etanercept, golimumab, infliximab, rituximab, and tocilizumab). For this study, data were presented from index date for the first 24 months for csDMARDs and bDMARDs.
Self-administered questionnaires concerning hormonal and reproductive factors, such as age at menopause and menarche, number of childbirths, abortion or miscarriage, duration of breastfeeding, hormonal birth control, and hormonal replacement therapy (HRT) were continuously sent out to female patients ≤80 years between two to five years after inclusion into the early arthritis cohort. In total, 1239 patients with early RA were eligible for the study but 40 were excluded as they had deceased after index date before receiving the questionnaire, six had developed dementia, another eight were not possible to identify due to wrong addresses, incorrect personal identification numbers or emigration and five did not want to participate. Of the remaining 1185 patients diagnosed with early RA, 928 (78.6%) patients completed the questionnaires and were included in the study (Figure 1). Further, 125 premenopausal patients who had answered the questionnaires were excluded from the analyses, since we have focused our analyses on postmenopausal women. We included women with natural or surgical (oophorectomy; n = 3) menopause. Reproductive lifespan was calculated as the time period in years between menarche and menopause. Information regarding smoking habits and body mass index (BMI kg2/m) was also asked for. The patients were classified either as being a non-smoker or ever-smoker (past or current).
Data regarding cardiovascular events (CVE) was obtained from the Swedish National Health Register and Cause of Death Register and were defined as hospital admissions or death as the underlying cause, e.g., ischemic stroke (ICD-10 codes I63.0–6, I63.8–9, I64.9, 165.0–3, 165.8–9), transient ischemic attack (ICD-10 code G45.9), amaurosis fugax (ICD-10 code G45.3), acute myocardial infarction (ICD-10 codes I21.0–4, I21.9, I22.0–1, I22.8–9, I24.8–9), unstable angina (ICD-10 code I20.0) or angina with presence of intervention (ICD-10 codes I20.1 or I20.8-9 together with Z95.1 or Z95.5 or FNG02 or FNG05 or FNC-10, -20, -30, -40, -50, -60 or FNC96) (Supplementary Table S1). Complementary data regarding diabetes mellitus and hypertension (defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) were collected from medical records besides diagnoses from the Swedish National Health Register (ICD-10 I10.9, I15.0-2, and I15.8-9).
The Regional Ethics Committee at the University Hospital in Umeå (Dnr 2019-03414, date 21 June 2019) approved the study. The participants gave their written informed consent and it was performed according to the Declaration of Helsinki.

2.2. Methods

Enzyme-linked immunosorbent assay (ELISA) was used to detect ACPA (anti-CCP2 antibodies) and performed according to the manufacturer’s instructions (Svar Life Science, Malmö, Sweden). The RF were analyzed using ELISA (Triolab, Mölndal, Sweden) and erythrocyte sedimentation rate (ESR; mm/h) according to Westergren method were analyzed at each hospital. Genotyping of HLA-DRB1 was performed as previously described [33]. HLA shared epitope (SE) was defined as HLA-DRB1*0401/0404/0405/0408/0101.
Radiographs of hands, wrists, and feet were assessed at index date and after 24 months and graded according to the Larsen score method [34] by two experienced readers (E.B. and S.R-D.).

2.3. Statistical Analyses

For analyses of categorical data, the chi-square test was used. For comparison of independent continuous variables between two groups, the Student’s t-test or the Mann–Whitney U test were used when appropriate. Cox proportional hazard regression analyses were used to take time into account for calculating hazard ratio (HR) and 95% confidence intervals (CI) of hormonal factors for CVE as dependent variable. Area under the curve (AUC) was calculated for cumulated values of DAS28 and ESR over the period of 24 months according to the trapezoid model (DAS28-AUC24 and ESR-AUC24, respectively) [35]. No significant differences were found among cases who did not respond on the questionnaires and those who did, concerned age at onset, smoking habits, frequency of anti-CCP or RF positivity, DAS28 and ESR at the index date or DAS28-AUC24. Since there were missing values in almost all covariates under consideration, we performed a sensitivity analysis using multiple imputation (MI) where missing covariate values were imputed using the other available covariates as well a crude estimate of cumulative baseline hazard as explanatory variables, as suggested by White and Royston [36]. We performed 10 imputations, using the default options in SPSS for determining imputation method for the respective variables as well as for pooling estimates. We did not include the Larsen Score variable in the multiple imputation as the fraction of missing data exceeded 50%. Two-sided p-values ≤ 0.05 were considered statistically significant. SPSS software (v. 26.0 IBM Corp, Armonk, NY, USA) was used for the statistical analyses.

3. Results

3.1. Characteristics of the Patients

Of the 803 postmenopausal female patients with early RA included in the study, a total of 103 patients had one or more CVE. Of them, 39 had their first event before they were diagnosed with or had their first symptoms of RA, mean (SD) 3.5 (5.2) years before RA onset and were thus excluded from further analysis. The other 64 patients had their first CVE after RA diagnosis. In the subsequent analyses, we have focused on comparing patients without CVE with those who had their first CVE after RA onset, since we wanted to focus on events in relation to RA. The total time at risk for first CVE after menopause was 7433 person-years and the incidence rate of first CVE was 7.76/1000 person-years.
Age at RA onset was significantly higher in patients who suffered from CVE compared to those without CVE (Table 1). Mean (SD) age for patients with CVE after RA onset was 59.7 (8.4) years compared with 56.6 (10.6) years in those without CVE (Table 1). DAS28-AUC during the first 24 months was significantly higher in those with CVE after RA onset compared with those without CVE. Traditional risk factors related to CVE such as smoking, hypertension, and diabetes were significantly increased in patients with CVE. Other characteristics including BMI at baseline, HLA-SE, and Larsen score at index date and 24 months, displayed no significant differences between the groups. DAS28-AUC24 was significantly higher in the cases affected with a CVE, although there were no differences in treatments with corticosteroids and DMARDs. We did not find significant relationships between age at onset and CVD risk factors, e.g., ever-smoking, or diabetes or DAS-AUC24 except for presence of hypertension that was related to age at onset. Regarding treatment, there were no differences between the groups (Table 1).

3.2. Hormonal Factors and Association to CVE

In the patients who had their first CVE after RA onset, the mean (SD) time from onset of RA to CVE was 7.4 (4.8) years and the postmenopausal time period was long until CVE was observed, mean time 17.4 years (10.1) (Table 2).
In patients who had a CVE, the time in years from menopause until RA onset was significantly longer (Table 3) and the proportion of postmenopausal patients at RA onset was significantly higher in comparison to those without CVEs. Patients with CVE after RA onset had a higher number of childbirths and were younger at first childbirth. In the group without CVE, the proportion of patients taking oral contraceptives was significantly higher compared with those with CVE. No significant differences were found for age at menarche, menopause or reproductive lifespan between the groups with similar results after multiple imputation (Table 3).

3.3. Cox Proportional Hazard Regression Analyses

In simple Cox proportional hazard regression models focusing on CVE after RA onset, higher risk of CVE was associated with age at debut, Larsen score at 24 months, number of children, number of children stratified into 3 groups, menopause (ref. before or after RA onset), years from menopause until RA onset, years from last childbirth to RA onset, and lower age at first childbirth besides having diabetes and hypertension (Table 4). In the multiple variable analyses, age at onset was not included as it correlated with Larsen score 24 months (rs = 0.27, p < 0.001), years from menopause to RA onset (rs = 0.904, p < 0.001), years from last childbirth (rs = 0.914, p < 0.001), and DAS-AUC24 (rs = 0.07, p = 0.049). In multiple variable analyses, the covariates being significant in simple variable analysis except for age at onset were included; the number of children calculated as continuous variable or stratified into 3 groups, and years from last childbirth remained significantly associated with having a CVE (Table 4a). Significance for diabetes and hypertension was lost. In another multiple variable analysis, the number of children calculated as continuous variable or stratified into 3 groups in separate analyses remained significant (HR = 1.842, 95%CI 1.345, 2.522, p < 0.001 and HR = 12.478, p = 0.002, 2df, respectively). Smoking, BMI, and use of oral contraceptives did not have a significant association with CVE. Furthermore, the significances for hypertension and diabetes were lost in multiple variable analysis. Analyses after multiple imputations presented in Table 4b yielded similar results except for significant effects of hypertension in the multiple variable analysis including number of children. The factors “Menopause before RA onset” and “Years between menopause and RA onset” were significantly related, whilst calculations performed including only one of the factors yielded similar non-significant results (HR = 1.028, 95%CI 0.414, 2.55, p = 0.053 and HR = 1.033, 95%CI 0.987, 1.08, p = 0.161, respectively). Further, no significant results were observed in the simple variable analyses of age at menopause, early menopause (≤45 years), reproductive life span, breastfeeding, HRT, progestagen, miscarriage or abortion, ESR-AUC24, HLA-SE, anti-CCP antibodies or RF.

4. Discussion

In this inception cohort of women with recent onset RA, we have evaluated hormonal and reproductive factors, and the reproductive lifespan in relation to development of CVE. Both RA and CVE are related to hormonal factors, and we have, in addition to Pfeifer et al., as one of the first studies analyzed the impact of these factors for CVE in RA [37].
According to our findings, the convincing majority of cases with later CVE had their RA disease onset after menopause. In nine cases with CVE, RA onset predated menopause, although the mean (SD) age at onset for the nine cases was 54 (4.3) years, suggesting a very late menopause. Patients with CVE after RA onset were significantly older compared with those without a CVE (p < 0.05) who had reached menopause. These findings suggest that it is not a long duration of disease burden in RA that account for the increased risk for CVE. Instead, the timing of disease development in relation to hormonal status appears to contribute most to the increased risk. This might be due to a certain vulnerability including aging blood vessels when getting RA after menopause when the hormonal protection of endogenous estrogen exposure is diminished. As reported elsewhere, the incidence of CVD is much lower in premenopausal than postmenopausal women in the general population [38], which we were able to confirm among the cases of this study. It has been suggested that estrogen has both long- and short-term effects on the blood vessel wall mediated by several mechanisms, which can partly explain our findings [39]. Estrogen receptors have been detected in smooth-muscle cells in coronary arteries [40] and data suggest that estrogen affects the bioavailability of endothelium-derived nitric oxide that can cause relaxation of vascular smooth-muscle cells. Thus, the vaso-protective effects of estrogen mediated by a large number of mechanisms could be reduced after menopause when estrogen levels are lower [39].
We were unable to confirm a relationship between reproductive lifespan, early menarche or early menopause and CVE in the present study. Others have reported that early menarche may increase the risk for both ischemic heart disease and stroke in the general population [20]. Early menopause has been associated both with development of RA [11], CVD in RA patients [37], and CVD in the general population [26,41]. A longer reproductive lifespan has been associated with a lower estimated risk of CVD in the general population [25,26,28], which we were unable to confirm. In this study, patients with CVE after RA onset had a slightly higher (18.8%) frequency of early menopause and a slightly shorter reproductive lifespan (mean 36.1 years), although not significantly different compared with RA patients without CVE (15.3% and mean 36.4 years, respectively).
Furthermore, in women of the general population, multiparity and childbirth at an early age increased the risk of CVE, as previously reported by others [20,42,43]. This was also the finding in our study. However, some studies have found a similar risk in men, suggesting that other factors than hormones play a role [21]. According to our findings, adjustments for the traditional risk factors such as smoking, hypertension, diabetes, BMI, and also age, did not reduce the significant results for multiparity and years from last childbirth to RA onset. However, due to lack of data, we have not performed any adjustments for lipid status, social, cultural, psychological, and behavioral factors associated with parenthood that could affect the development of CVEs.
Duration of breastfeeding and frequency of women breastfeeding did not differ between the groups, although we found a tendency for more frequent breastfeeding and longer duration in women with CVE after RA onset. Several others have reported that breastfeeding may decrease the risk for CVD in hospitalization cases or CVD mortality, but our findings did not confirm this [24,43].
In contrary to other studies on the general population [23], we were unable to conclude that oral contraceptives increase the risk of CVE. Controversially, our results showed a tendency towards protective effects of oral contraceptives irrespective of treatment duration. In previous studies on oral contraceptives in RA, a protective effect was found for disease development, particularly in ACPA-positive RA [12]. Furthermore, we have reported in a previous study that disease development of RA was postponed with oral contraceptives [44].
Hormone replacement therapy has been suggested to increase the risk for RA [45], whilst another study reported a decreased risk in ACPA-positive RA [13]. Furthermore, findings in the general population suggest that HRT has negative effects on CVD and CVE, e.g., increased risk for stroke, venous and pulmonary thromboembolism, probably by affecting lipids, lipoproteins, inflammation, and hemostasis [46]. We found no effect of HRT for the risk of CVE, although the levels of these mentioned factors were not analyzed in this study.
We cannot explain the presence of CVE by higher age at disease onset or longer time from menopause to RA onset by the traditional risk factors. Presence of ever-smoking, diabetes or higher disease activity was not related to age, except for hypertension. The RA patients with CVE had significantly higher DAS28-AUC24 compared with those without a CVE, although the treatment with corticosteroids and DMARDs were similar in both groups. The significance of DAS28-AUC24 was lost when time was taken into account in the Cox proportional hazard regression analyses. A relationship between CVD and inflammation has been demonstrated in other studies, which we were unable to confirm in this study [47,48]. However, this was not our main focus in our study, and the only measurements of inflammation were DAS28-AUC24 and ESR-AUC24.
A strength of the current study was that the cohort of early RA patients was unselected and subsequently included and originated from a homogenous population of northern Sweden. Almost all individuals were willing to participate and to be included in this study (80%), of those diagnosed with early RA and younger than 80 years of age, within the catchment area of northern Sweden. Another strength is that we have chosen a rather strict definition for CVEs and have not included all types of cardio- and cerebrovascular diseases. This strict definition decreases the risk of including patients with other causes for cardio- and cerebrovascular diseases. In contrary to some other studies, patients with other cardio-and cerebrovascular diseases such as congestive heart failure and cerebral hemorrhage were not included, although these conditions might also have been affected by hormonal and reproductive factors and the RA disease. Moreover, in our analyses, we have performed adjustments for traditional risk factors. We could confirm that the RA patients with CVE had higher frequencies of being a smoker, hypertension and/or diabetes mellitus compared with those without an event, although these factors were not significant in multiple variable analyses.
Although this study included a fairly large number of patients, stratification into subgroups resulted in a limited number of cases. Another limitation could be the difficulties in accurately recalling past hormonal events. Even though the agreement has been shown to be high between medical records and interview data regarding the duration and use of oral contraceptives, women might have difficulties in accurately recalling what specific types of preparations they have used [49,50]. Furthermore, age at menopause and menarche can be hard to remember exactly, especially since menopause does not occur at one specific time point. A larger patient material could help to overcome some of the limitations. Another limitation is that we did not have a control group from the general population to compare with. Additionally, more information about CVD risk factors and CVD medications would be informative in the RA cases and in the controls. There may, of course, be residual confounding factors we are unaware of or a lack of data for analysis.
The aim of this study was to evaluate the contribution of hormonal and reproductive factors for the development of CVE in patients with early RA. Some of the factors seem to act similarly for the two diseases with increasing or decreasing the risk, where previous studies have described contradictory effects [11,20]. Number of pregnancies increased the risk for CVE in RA as previously reported for CVD in the population [20,42]. The reproductive lifespan tended to be shorter in our cases with CVE, although not significantly, in line with previous findings on the general population [25,26,27,51]. Early menopause also tended to be of higher frequency, 18.8% vs. 15.3% in RA cases with CVE, but not significantly, whilst pregnancy at an early age was significantly associated with CVE in RA as has been reported for both CVD and RA per se [11,20,22,52]. The risk contribution of oral contraceptives on RA disease onset have been presented with contradictory results previously [11,53,54,55,56], whilst most studies have reported an increased risk for CVD in the general population [23]. It is evident that the hormonal and reproductive factors act both similarly and differently in these two diseases, which makes it difficult to conclude about interactive effects. However, we found that the significance of hypertension and diabetes was lost in multiple variable analyses, whilst the number of childbirths remained.

5. Conclusions

In summary, this is one of the first studies exploring the impact of hormonal and reproductive factors for CVE in women affected with RA. Female RA patients with CVE had a late RA disease onset, in most cases, after menopause. A higher number of childbirths increased the risk for CVE, as well as years from last childbirth, irrespective of traditional risk factors. Several other hormonal and reproductive factors showed a trend for increased risk of CVE, such as early menopause, pregnancy at an early age, and reproductive life span, although not significantly. Larger studies are needed to evaluate this further. The DAS28-AUC24 was higher in cases with a CVE, although that was lost when time was taken into account. It is evident that the hormonal and reproductive factors act both similarly and differently in RA versus the general population, which makes it difficult to conclude about the interactive effects of these factors in RA and CVE per se. Understanding the role of female hormonal factors is of key importance for the identification of women at high risk for CVE so that preventive strategies can be initiated. These findings help to identify factors that can cause increased mortality and morbidity in women with RA besides disease-related factors and traditional risk factors for CVD.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm12010208/s1, Table S1: Included diagnoses defined as cardiovascular event (CVE).

Author Contributions

Conceptualization, A.B. and S.R.-D.; data curation, A.B. and S.R.-D.; formal analysis, A.B. and S.R.-D.; methodology, A.B., H.K., E.B., G.-M.A. and S.R.-D.; writing—original draft, A.B.; writing—review and editing, H.K., E.B., G.-M.A. and S.R.-D. All authors were involved in drafting the article or revising it critically for important intellectual content. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grants from the Swedish Research Council (Dnr:2018-02551); King Gustaf V’s 80-Year Fund; the Swedish Rheumatism Association, and Umeå University.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee at Umeå University (Dnr 2019-03414, approved 21 June 2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data will be available after contact with the corresponding author. This cohort of patients are included in a large cohort where statistical work and evaluation is ongoing.

Acknowledgments

We would like to acknowledge the staff and the patients at the departments of Rheumatology in northern Sweden (Sunderbyn, Umeå, Örnsköldsvik, Sundsvall, and Östersund). Anders Lundquist, is gratefully acknowledged for statistical support.

Conflicts of Interest

The authors have declared no conflicts of interest.

References

  1. Wallberg-Jonsson, S.; Ohman, M.L.; Dahlqvist, S.R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J. Rheumatol. 1997, 24, 445–451. [Google Scholar] [PubMed]
  2. Avina-Zubieta, J.A.; Thomas, J.; Sadatsafavi, M.; Lehman, A.J.; Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Ann. Rheum. Dis. 2012, 71, 1524–1529. [Google Scholar] [CrossRef] [PubMed]
  3. Maradit-Kremers, H.; Crowson, C.S.; Nicola, P.J.; Ballman, K.V.; Roger, V.L.; Jacobsen, S.J.; Gabriel, S.E. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheumatol. 2005, 52, 402–411. [Google Scholar] [CrossRef] [PubMed]
  4. Roman, M.J.; Salmon, J.E. Cardiovascular manifestations of rheumatologic diseases. Circulation 2007, 116, 2346–2355. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Nicola, P.J.; Maradit-Kremers, H.; Roger, V.L.; Jacobsen, S.J.; Crowson, C.S.; Ballman, K.V.; Gabriel, S.E. The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis Rheumatol. 2005, 52, 412–420. [Google Scholar] [CrossRef] [PubMed]
  6. England, B.R.; Thiele, G.M.; Anderson, D.R.; Mikuls, T.R. Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications. BMJ 2018, 361, k1036. [Google Scholar] [CrossRef]
  7. Westerlind, H.; Rönnelid, J.; Hansson, M.; Alfredsson, L.; Mathsson-Alm, L.; Serre, G.; Cornillet, M.; Holmdahl, R.; Jakobsson, P.J.; Skriner, K.; et al. Anti-Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2020, 72, 1658–1667. [Google Scholar] [CrossRef]
  8. Radu, A.F.; Bungau, S.G. Management of Rheumatoid Arthritis: An Overview. Cells 2021, 10, 2857. [Google Scholar] [CrossRef]
  9. Parikh, N.I.; Jeppson, R.P.; Berger, J.S.; Eaton, C.B.; Kroenke, C.H.; LeBlanc, E.S.; Lewis, C.E.; Loucks, E.B.; Parker, D.R.; Rillamas-Sun, E.; et al. Reproductive Risk Factors and Coronary Heart Disease in the Women’s Health Initiative Observational Study. Circulation 2016, 133, 2149–2158. [Google Scholar] [CrossRef] [Green Version]
  10. Merritt, M.A.; Riboli, E.; Murphy, N.; Kadi, M.; Tjonneland, A.; Olsen, A.; Overvad, K.; Dossus, L.; Dartois, L.; Clavel-Chapelon, F.; et al. Reproductive factors and risk of mortality in the European Prospective Investigation into Cancer and Nutrition; a cohort study. BMC Med. 2015, 13, 252. [Google Scholar] [CrossRef]
  11. Alpizar-Rodriguez, D.; Pluchino, N.; Canny, G.; Gabay, C.; Finckh, A. The role of female hormonal factors in the development of rheumatoid arthritis. Rheumatology 2017, 56, 1254–1263. [Google Scholar] [CrossRef] [Green Version]
  12. Orellana, C.; Saevarsdottir, S.; Klareskog, L.; Karlson, E.W.; Alfredsson, L.; Bengtsson, C. Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: Results from the Swedish EIRA study. Ann. Rheumatol. Dis. 2017, 76, 1845–1852. [Google Scholar] [CrossRef] [Green Version]
  13. Orellana, C.; Saevarsdottir, S.; Klareskog, L.; Karlson, E.W.; Alfredsson, L.; Bengtsson, C. Postmenopausal hormone therapy and the risk of rheumatoid arthritis: Results from the Swedish EIRA population-based case-control study. Eur. J. Epidemiol. 2015, 30, 449–457. [Google Scholar] [CrossRef] [Green Version]
  14. Tang, M.W.; Garcia, S.; Gerlag, D.M.; Tak, P.P.; Reedquist, K.A. Insight into the Endocrine System and the Immune System: A Review of the Inflammatory Role of Prolactin in Rheumatoid Arthritis and Psoriatic Arthritis. Front. Immunol. 2017, 8, 720. [Google Scholar] [CrossRef] [Green Version]
  15. Ostensen, M.; Aune, B.; Husby, G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand. J. Rheumatol. 1983, 12, 69–72. [Google Scholar] [CrossRef]
  16. Barrett, J.H.; Brennan, P.; Fiddler, M.; Silman, A.J. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheumatol. 1999, 42, 1219–1227. [Google Scholar] [CrossRef]
  17. Wong, L.E.; Huang, W.T.; Pope, J.E.; Haraoui, B.; Boire, G.; Thorne, J.C.; Hitchon, C.A.; Tin, D.; Keystone, E.C.; Bykerk, V.P.; et al. Effect of age at menopause on disease presentation in early rheumatoid arthritis: Results from the Canadian Early Arthritis Cohort. Arthritis Care Res. 2015, 67, 616–623. [Google Scholar] [CrossRef]
  18. Kvien, T.K.; Uhlig, T.; Odegard, S.; Heiberg, M.S. Epidemiological aspects of rheumatoid arthritis: The sex ratio. Ann. N. Y. Acad. Sci. 2006, 1069, 212–222. [Google Scholar] [CrossRef]
  19. Canoy, D.; Beral, V.; Balkwill, A.; Wright, F.L.; Kroll, M.E.; Reeves, G.K.; Green, J.; Cairns, B.J.; Million Women Study, C. Age at menarche and risks of coronary heart and other vascular diseases in a large UK cohort. Circulation 2015, 131, 237–244. [Google Scholar] [CrossRef] [Green Version]
  20. Peters, S.A.; Woodward, M. Women’s reproductive factors and incident cardiovascular disease in the UK Biobank. Heart 2018, 104, 1069–1075. [Google Scholar] [CrossRef]
  21. Lawlor, D.A.; Emberson, J.R.; Ebrahim, S.; Whincup, P.H.; Wannamethee, S.G.; Walker, M.; Smith, G.D.; British Women’s, H.; Health, S.; British Regional Heart, S. Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associated with child-rearing? Findings from the British Women’s Heart and Health Study and the British Regional Heart Study. Circulation 2003, 107, 1260–1264. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Rosendaal, N.T.A.; Alvarado, B.; Wu, Y.Y.; Velez, M.P.; da Camara, S.M.A.; Pirkle, C.M. Adolescent Childbirth Is Associated With Greater Framingham Risk Scores for Cardiovascular Disease Among Participants of the IMIAS (International Mobility in Aging Study). J. Am. Heart Assoc. 2017, 6, e007058. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Roach, R.E.; Helmerhorst, F.M.; Lijfering, W.M.; Stijnen, T.; Algra, A.; Dekkers, O.M. Combined oral contraceptives: The risk of myocardial infarction and ischemic stroke. Cochrane Database Syst. Rev. 2015, 8, CD011054. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Nguyen, B.; Gale, J.; Nassar, N.; Bauman, A.; Joshy, G.; Ding, D. Breastfeeding and Cardiovascular Disease Hospitalization and Mortality in Parous Women: Evidence From a Large Australian Cohort Study. J. Am. Heart Assoc. 2019, 8, e011056. [Google Scholar] [CrossRef] [PubMed]
  25. Mishra, S.R.; Waller, M.; Chung, H.F.; Mishra, G.D. Association of the length of oestrogen exposure with risk of incident stroke in postmenopausal women: Insights from a 20-year prospective study. Int. J. Cardiol. 2021, 328, 206–214. [Google Scholar] [CrossRef]
  26. Ley, S.H.; Li, Y.; Tobias, D.K.; Manson, J.E.; Rosner, B.; Hu, F.B.; Rexrode, K.M. Duration of Reproductive Life Span, Age at Menarche, and Age at Menopause Are Associated With Risk of Cardiovascular Disease in Women. J. Am. Heart Assoc. 2017, 6, e006713. [Google Scholar] [CrossRef] [Green Version]
  27. Mishra, S.R.; Chung, H.F.; Waller, M.; Dobson, A.J.; Greenwood, D.C.; Cade, J.E.; Giles, G.G.; Bruinsma, F.; Simonsen, M.K.; Hardy, R.; et al. Association Between Reproductive Life Span and Incident Nonfatal Cardiovascular Disease: A Pooled Analysis of Individual Patient Data from 12 Studies. JAMA Cardiol. 2020, 5, 1410–1418. [Google Scholar] [CrossRef]
  28. Kim, S.H.; Sim, M.Y.; Park, S.B. Association between duration of reproductive lifespan and Framingham risk score in postmenopausal women. Maturitas 2015, 82, 431–435. [Google Scholar] [CrossRef]
  29. Arnett, F.C.; Edworthy, S.M.; Bloch, D.A.; McShane, D.J.; Fries, J.F.; Cooper, N.S.; Healey, L.A.; Kaplan, S.R.; Liang, M.H.; Luthra, H.S.; et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatol. 1988, 31, 315–324. [Google Scholar] [CrossRef]
  30. Svensk Reumatologis Kvalitetsregister. Available online: https://srq.nu (accessed on 30 October 2022).
  31. Prevoo, M.L.; van’t Hof, M.A.; Kuper, H.H.; van Leeuwen, M.A.; van de Putte, L.B.; van Riel, P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheumatol 1995, 38, 44–48. [Google Scholar] [CrossRef]
  32. Van Gestel, A.M.; Haagsma, C.J.; van Riel, P.L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheumatol 1998, 41, 1845–1850. [Google Scholar] [CrossRef]
  33. Kokkonen, H.; Johansson, M.; Innala, L.; Jidell, E.; Rantapaa-Dahlqvist, S. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res. Ther. 2007, 9, R56. [Google Scholar] [CrossRef] [Green Version]
  34. Larsen, A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J. Rheumatol. 1995, 22, 1974–1975. [Google Scholar]
  35. Matthews, J.N.; Altman, D.G.; Campbell, M.J.; Royston, P. Analysis of serial measurements in medical research. BMJ 1990, 300, 230–235. [Google Scholar] [CrossRef] [Green Version]
  36. White, I.R.; Royston, P.; Wood, A.M. Multiple imputation using chained equations: Issues and guidance for practice. Stat. Med. 2011, 30, 377–399. [Google Scholar] [CrossRef]
  37. Pfeifer, E.C.; Crowson, C.S.; Amin, S.; Gabriel, S.E.; Matteson, E.L. The influence of early menopause on cardiovascular risk in women with rheumatoid arthritis. J. Rheumatol. 2014, 41, 1270–1275. [Google Scholar] [CrossRef] [Green Version]
  38. Gordon, T.; Kannel, W.B.; Hjortland, M.C.; McNamara, P.M. Menopause and coronary heart disease. The Framingham Study. Ann. Intern. Med. 1978, 89, 157–161. [Google Scholar] [CrossRef]
  39. Mendelsohn, M.E.; Karas, R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 1999, 340, 1801–1811. [Google Scholar] [CrossRef]
  40. Gruber, C.J.; Tschugguel, W.; Schneeberger, C.; Huber, J.C. Production and actions of estrogens. N. Engl. J. Med. 2002, 346, 340–352. [Google Scholar] [CrossRef]
  41. Wellons, M.; Ouyang, P.; Schreiner, P.J.; Herrington, D.M.; Vaidya, D. Early menopause predicts future coronary heart disease and stroke: The Multi-Ethnic Study of Atherosclerosis. Menopause 2012, 19, 1081–1087. [Google Scholar] [CrossRef] [Green Version]
  42. Ness, R.B.; Harris, T.; Cobb, J.; Flegal, K.M.; Kelsey, J.L.; Balanger, A.; Stunkard, A.J.; D’Agostino, R.B. Number of pregnancies and the subsequent risk of cardiovascular disease. N. Engl. J. Med. 1993, 328, 1528–1533. [Google Scholar] [CrossRef] [PubMed]
  43. Peters, S.A.; van der Schouw, Y.T.; Wood, A.M.; Sweeting, M.J.; Moons, K.G.; Weiderpass, E.; Arriola, L.; Benetou, V.; Boeing, H.; Bonnet, F.; et al. Parity, breastfeeding and risk of coronary heart disease: A pan-European case-cohort study. Eur. J. Prev. Cardiol. 2016, 23, 1755–1765. [Google Scholar] [CrossRef] [PubMed]
  44. Berglin, E.; Kokkonen, H.; Einarsdottir, E.; Agren, A.; Rantapää Dahlqvist, S. Influence of female hormonal factors, in relation to autoantibodies and genetic markers, on the development of rheumatoid arthritis in northern Sweden: A case-control study. Scand. J. Rheumatol. 2010, 39, 454–460. [Google Scholar] [CrossRef] [PubMed]
  45. Merlino, L.A.; Cerhan, J.R.; Criswell, L.A.; Mikuls, T.R.; Saag, K.G. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin. Arthritis Rheumatol. 2003, 33, 72–82. [Google Scholar] [CrossRef] [PubMed]
  46. Howard, B.V.; Rossouw, J.E. Estrogens and cardiovascular disease risk revisited: The Women’s Health Initiative. Curr. Opin. Lipidol. 2013, 24, 493–499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Innala, L.; Moller, B.; Ljung, L.; Magnusson, S.; Smedby, T.; Sodergren, A.; Ohman, M.L.; Rantapaa-Dahlqvist, S.; Wallberg-Jonsson, S. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: A five year prospective study. Arthritis Res. Ther. 2011, 13, R131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Solomon, D.H.; Reed, G.W.; Kremer, J.M.; Curtis, J.R.; Farkouh, M.E.; Harrold, L.R.; Hochberg, M.C.; Tsao, P.; Greenberg, J.D. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015, 67, 1449–1455. [Google Scholar] [CrossRef] [Green Version]
  49. Nischan, P.; Ebeling, K.; Thomas, D.B.; Hirsch, U. Comparison of recalled and validated oral contraceptive histories. Am. J. Epidemiol. 1993, 138, 697–703. [Google Scholar] [CrossRef]
  50. Norell, S.E.; Boethius, G.; Persson, I. Oral contraceptive use: Interview data versus pharmacy records. Int. J. Epidemiol. 1998, 27, 1033–1037. [Google Scholar] [CrossRef]
  51. Alonso de Lecinana, M.; Egido, J.A.; Fernandez, C.; Martinez-Vila, E.; Santos, S.; Morales, A.; Martinez, E.; Pareja, A.; Alvarez-Sabin, J.; Casado, I.; et al. Risk of ischemic stroke and lifetime estrogen exposure. Neurology 2007, 68, 33–38. [Google Scholar] [CrossRef]
  52. Orellana, C.; Wedrén, S.; Källberg, H.; Holmqvist, M.; Karlson, E.W.; Alfredsson, L.; Bengtsson, C. Parity and the risk of developing rheumatoid arthritis: Results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis study. Ann. Rheumatol. Dis. 2014, 73, 752–755. [Google Scholar] [CrossRef]
  53. Doran, M.F.; Crowson, C.S.; O’Fallon, W.M.; Gabriel, S.E. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: A population based study. J. Rheumatol. 2004, 31, 207–213. [Google Scholar]
  54. Hazes, J.M.; van Zeben, D. Oral contraception and its possible protection against rheumatoid arthritis. Ann. Rheum. Dis. 1991, 50, 72–74. [Google Scholar] [CrossRef] [Green Version]
  55. Brennan, P.; Bankhead, C.; Silman, A.; Symmons, D. Oral contraceptives and rheumatoid arthritis: Results from a primary care-based incident case-control study. Semin. Arthritis Rheum. 1997, 26, 817–823. [Google Scholar] [CrossRef]
  56. Moskowitz, M.A.; Jick, S.S.; Burnside, S.; Wallis, W.J.; Dickson, J.F.; Hunter, J.R.; Jick, H. The relationship of oral contraceptive use to rheumatoid arthritis. Epidemiology 1990, 1, 153–156. [Google Scholar] [CrossRef]
Jcm 12 00208 g001 550
Figure 1. Flowchart illustrating the inception cohort of RA patients.
Figure 1. Flowchart illustrating the inception cohort of RA patients.
Jcm 12 00208 g001
Table
Table 1. Baseline characteristics of RA patients without CVE and CVE after RA onset.
Table 1. Baseline characteristics of RA patients without CVE and CVE after RA onset.
Baseline CharacteristicsNo CVECVE after
RA Onset
(n = 700)(n = 64)
Age at RA onset, years, mean (SD)56.6 (10.6)59.7 (8.4) *
Follow-up time, years, mean (SD)10.0 (5.5)12.9 (4.9) ***
DAS28-AUC24, mean (SEM) 186.0 (0.9)92.3 (3.0) *
ESR-AUC24, mean (SEM) 2510.6 (11.2)573.9 (40.6)
Ever-smoker, n (%)360/603 (59.7)45/61 (73.8) *
Hypertension, n (%)114/356 (32.0)39/64 (60.9) ***
Diabetes mellitus, n (%)24/356 (6.7)11/64 (17.2) **
BMI, kg/m2, mean (SEM) 326.3 (0.2)26.6 (0.5)
HLA-SE, n (%)394/550 (71)45/57 (78.9)
Larsen score baseline, median (IQR) 45.0 (8.0)8.0 (11.0)
Larsen score at 24 months, median (IQR) 59.0 (8.0)12.0 (12.5)
Radiological progression, yes/no, n (%)70/180 (38.9)10/29 (34.5)
Anti-CCP2 positivity, n (%)422/610 (69.2)39/60 (65.0)
RF positivity, n (%)455/598 (76)43/58 (74.1)
Corticosteroids at baseline, n (%)353/572 (61)37/61 (60.7)
Corticosteroids still at 24 months, n (%)151/452 (33.4)17/57 (29.8)
csDMARDs at baseline, n (%)609/675 (90)58/64 (90.6)
Methotrexate at baseline, n (%)550/669 (82.2)55/63 (87.3)
csDMARDs ever, n (%)677/680 (99)63/64 (98.4)
bDMARDs ever, n (%)112/689 (16.3)6/64 (9.4)
bDMARD within 24 months, n (%)100/689 (14.5)5/64 (7.8)
* Significance to reference (no CVE) * p < 0.05, ** p < 0.01, *** p < 0.001. Anti-CCP2, anticyclic citrullinated; peptide-2; AUC, area under the curve; bDMARDs, biological disease-modifying antirheumatic drugs; BMI, body mass index; csDMARDs, conventional disease-modifying antirheumatic drugs; DAS, disease activity score; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor. Number of cases with data before imputation 1 n = 691 and 64, 2 n = 700 and 64, 3 n = 608 and 58, 4 n = 275 and 33, 5 n = 256 and 31, respectively.
Table
Table 2. Characteristics of patients with their first CVE after (n = 64) RA onset.
Table 2. Characteristics of patients with their first CVE after (n = 64) RA onset.
Characteristics of PatientsCVE after
RA Onset
(n = 64)
Age at event, years, mean (SD)67.1 (8.6)
Duration of RA until CVE, years, mean (SD)7.4 (4.8)
Number of CVE per individual, mean (SD)1.2 (0.4)
Individuals at menopause at CVE, n (%)60 (93.8)
Years from menopause until CVE, mean (SD)17.4 (10.1)
Years from last childbirth until CVE, years, mean (SD)39.4 (12.0)
TIA, AF or ischemic stroke, n (%)37 (58.7)
MI or AP with intervention, n (%)31 (48.4)
CVE as cause of death after RA onset, n (%)4 (6.3)
AF, amaurosis fugax; AP, angina pectoris; CVE, cardiovascular event; MI, myocardial infarction; TIA, transient ischemic attack.
Table
Table 3. Characteristics of hormonal and reproductive factors in patients with no CVE (n = 700), and CVE after RA onset (n = 64).
Table 3. Characteristics of hormonal and reproductive factors in patients with no CVE (n = 700), and CVE after RA onset (n = 64).
Hormonal and Reproductive FactorsNo CVECVE after RA
(n = 700)(n = 64)
Age at menarche, mean (SD), years13.2 (1.4)13.4 (1.4)
Age at menopause, mean (SD), years49.8 (4.4)49.5 (5.3)
Early menopause (≤45 years), n (%)107 (15.3)12 (18.8)
Years from menopause until RA onset, mean (SD)6.7 (11.2)10.2 (9.8) *
Individuals at menopause at RA onset, n (%)517 (73.9)55 (85.9) *
Childbirth before RA onset, n (%)622 (90.3)61 (95.3)
Number of childbirths, median (IQR)2.0 (2.0)2.0 (1.0) *
Age at first childbirth before RA onset, mean (SD)24.2 (4.7)22.9 (4.2) *
Age at last childbirth before RA onset, mean, (SD)29.3 (5.3)29.1 (5.5)
Years from last childbirth until RA onset, mean (SD), years27.8 (11.8)30.8 (10.4)
Miscarriage or abortion, n (%)247 (36.8)19 (30.2)
Breastfeeding, n (%)572 (92.0)57 (93.4)
Total duration of breastfeeding months, mean (SD)12.7 (12.4)13.4 (12.1)
Oral contraceptives, n (%)438 (63.3)32 (50.0) *
Oral contraceptives, mean (SD), years3.7 (5.5)2.5 (4.2)
Progestagen, n (%)182 (26.7)14 (21.9)
Progestagen, mean (SD), years2.0 (5.0)2.1 (6.4)
HRT before RA onset, n (%)184 (27.6)16 (25.4)
HRT, mean (SD), years6.4 (6.3)6.1 (6.6)
Reproductive lifespan, mean (SD), years36.4 (5.2)
(n = 559) 1		36.2 (5.5)
(n = 59) 1
* CVE after RA onset vs. reference (no CVD); * p < 0.05, CVE, cardiovascular event; HRT, hormone replacement therapy, 1 number of included cases.
Table
Table 4. (a). Simple and multiple variables in Cox proportional hazard regression analysis of CVE after RA onset as dependent variable (n = 64) versus no CVD (n = 700). Complete case analyses. (b). Simple and multiple variables in Cox proportional hazard regression analysis of CVE after RA onset as dependent variable (n = 64) versus no CVD (n = 700). Multiple imputation results.
Table 4. (a). Simple and multiple variables in Cox proportional hazard regression analysis of CVE after RA onset as dependent variable (n = 64) versus no CVD (n = 700). Complete case analyses. (b). Simple and multiple variables in Cox proportional hazard regression analysis of CVE after RA onset as dependent variable (n = 64) versus no CVD (n = 700). Multiple imputation results.
(a)
CovariatesSimple Variable AnalysisMultiple Variable AnalysisMultiple Variable Analysis
HR95%CIp-ValueHR95%CIp-ValueHR95%CIp-Value
Age at onset, years1.1011.067, 1.1360.000- -
Ever smoker1.5720.889, 2.7830.120
Larsen score at 24 months1.0350.998, 1.0740.065 .
Children, n1.3661.114, 1.6750.0031.8421.345, 2.5220.000
Children (3 groups)8.415 0.015 12.478 ‡ 0.002
≤1 childRef.
2 children1.7950.890, 3.6210.102 3.1951.309, 7.8010.011
≥3 children2.8161.382, 5.7350.004 5.6732.147, 14.9900.000
Menopause before RA onset, yes1.9821.024, 3.8370.0421.2280.479, 3.1480.6691.3360.513, 3.4800.553
Years between menopause and RA onset1.0651.036, 1.0940.0001.0260.977, 1.0780.3041.0340.985, 1.0840.177
Oral contraceptives, yes0.7150.438, 1.1690.181
Age at first childbirth, years0.9410.882, 1.0040.0671.013 ‡0.933, 1.0990.7611.010 ‡0.931, 1.0960.813
Years from last childbirth to RA onset, years1.0701.042, 1.0990.0001.0671.010, 1.1260.0201.0601.004, 1.1200.034
DAS28-AUC24m1.0040.994, 1.0150.431
Diabetes2.2421.166, 4.3090.0151.0880.499, 2.3680.8331.2100.554, 2.6420.633
Hypertension2.7801.659, 4.6590.0001.6760.971, 2.8920.0641.6350.944, 2.8320.079
BMI1.0240.966, 1.0850.426
Wald statistic for overall significance test. ‡ Included since it was significant in the multiple imputation analysis.
(b)
CovariatesSimple Variable AnalysisMultiple Variable AnalysisMultiple Variable Analysis
HR95%CIp-ValueHR95%CI HR
Age at onset, years1.1011.067, 1.1360.000- -
Ever smoker1.5440.869, 2.7460.139
Larsen score at 24 months †1.0350.998, 1.0740.065
Children, n1.3661.114, 1.6750.0031.6701.268, 2.2000.000
Children (3 groups)8.415 0.015 12.478 0.002
≤1 childRef.
2 children1.7950.890, 3.6210.102 2.7531.272, 5.9580.010
≥3 children2.8161.382, 5.7350.004 4.7772.003, 11.3930.000
Menopause before RA onset, yes3.6681.901, 7.07710.0001.1980.473, 3.0360.4731.2560.105, 2.4590.401
Years between menopause and RA onset1.0771.051, 1.1050.0001.0360.988, 1.0860.1461.0410.994, 1.0910.089
Oral contraceptives, yes0.7020.429, 1.1480.159
Age at first childbirth, years0.9360.878, 0.9990.0471.0180.941, 1.1010.6551.0190.942, 1.1010.645
Years from last childbirth to RA onset, years1.0661.039, 1.0940.0001.0601.006, 1.1160.0281.0571.004, 1.1120.033
DAS28-AUC24m1.0040.994, 1.0150.429
Diabetes2.2651.173, 4.3710.0151.4270.715, 2.8490.3141.5270.764, 3.0530.231
Hypertension2.8021.671, 4.7000.0001.7321.008, 2.9760.0471.6860.979, 2.9040.060
BMI1.0250.967, 1.0870.404
Wald statistic for overall significance test. The Wald test is not pooled, i.e., complete case results shown for overall test. † Not imputed as the fraction of missing exceeded 50%.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Boman, A.; Kokkonen, H.; Berglin, E.; Alenius, G.-M.; Rantapää-Dahlqvist, S. Hormonal and Reproductive Factors in Relation to Cardiovascular Events in Women with Early Rheumatoid Arthritis. J. Clin. Med. 2023, 12, 208. https://doi.org/10.3390/jcm12010208

AMA Style

Boman A, Kokkonen H, Berglin E, Alenius G-M, Rantapää-Dahlqvist S. Hormonal and Reproductive Factors in Relation to Cardiovascular Events in Women with Early Rheumatoid Arthritis. Journal of Clinical Medicine. 2023; 12(1):208. https://doi.org/10.3390/jcm12010208

Chicago/Turabian Style

Boman, Antonia, Heidi Kokkonen, Ewa Berglin, Gerd-Marie Alenius, and Solbritt Rantapää-Dahlqvist. 2023. "Hormonal and Reproductive Factors in Relation to Cardiovascular Events in Women with Early Rheumatoid Arthritis" Journal of Clinical Medicine 12, no. 1: 208. https://doi.org/10.3390/jcm12010208

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop